- Previous Close
3,978.00 - Open
3,976.00 - Bid 4,024.00 x --
- Ask 4,040.00 x --
- Day's Range
3,962.00 - 4,113.00 - 52 Week Range
3,600.00 - 4,735.00 - Volume
215,500 - Avg. Volume
175,111 - Market Cap (intraday)
293.562B - Beta (5Y Monthly) --
- PE Ratio (TTM)
19.19 - EPS (TTM)
209.70 - Earnings Date Apr 10, 2025
- Forward Dividend & Yield 86.00 (2.14%)
- Ex-Dividend Date Feb 27, 2025
- 1y Target Est
4,700.00
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. The company exports its products to Asia, the United States of America, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.
www.global.hisamitsu2,759
Full Time Employees
February 29
Fiscal Year Ends
Sector
Recent News: 4530.T
View MorePerformance Overview: 4530.T
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4530.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4530.T
View MoreValuation Measures
Market Cap
293.56B
Enterprise Value
179.85B
Trailing P/E
19.19
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.99
Price/Book (mrq)
1.13
Enterprise Value/Revenue
1.20
Enterprise Value/EBITDA
8.19
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
150.13B
Net Income Avi to Common (ttm)
15.54B
Diluted EPS (ttm)
209.70
Balance Sheet and Cash Flow
Total Cash (mrq)
116.64B
Total Debt/Equity (mrq)
1.12%
Levered Free Cash Flow (ttm)
--